Share this article
Share this article
SANTA CLARA, Calif., Dec. 15, 2020 /PRNewswire/ Marvell Technology Group Ltd. (NASDAQ: MRVL) ( Marvell ), a leading provider of data infrastructure semiconductor solutions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ( HSR Act ), as amended, in connection with its previously announced proposed acquisition of Inphi Corporation ( Inphi ), expired at 11:59 p.m. EST on December 14, 2020.
The expiration of the HSR Act waiting period satisfies one of the conditions to the closing of the proposed acquisition, which remains subject to other customary closing conditions, including receipt of shareholder approvals and other regulatory approvals.
Gilead Sciences to acquire MYR - Pharmaceutical Business review
pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Gilead Sciences to Acquire MYR GmbH - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.
Share:
FOSTER CITY, Calif. and BAD HOMBURG, Germany, Dec. 10, 2020 /PRNewswire/ Gilead Sciences, Inc. (NASDAQ:GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million (both payments subject to customary adjustments).
The acquisition will provide Gilead with Hepcludex
™ (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. MYR has since launched Hepcludex in France, Germany and Austria, and continues to prepare for launch in certain other markets throughout 2021. It is e